Home » Newsletters » BioWorld

BioWorld

Nov. 16, 2009

View Archived Issues

Maxygen Buying Back Stock; Analysts Say No Trend Here

Maxygen Inc. on Friday became the latest member of a very small biotech cadre that is returning cash to shareholders. (BioWorld Today) Read More

Fate Raises $30M in Series B to Advance Stem Cell Product

Study Links Oxidative Damage to BAK, and to Hearing Loss

BioWorld Today Introduces New 'Bench Press' Section

Lawmaker Quizzing Military on Antidepressants, Suicides

Further Troubles at Allston Plant Send Genzyme Shares Sliding

Other News To Note

Clinic Roundup

Appointments And Advancements

Bench Press